City of Hope Doctors Present New Research on Bone Marrow Transplants, Immunotherapy and Other Blood Cancer Treatments

Data will be presented at virtual American Society of Hematology (ASH) Annual Meeting Dec. 5 to 8

DUARTE, Calif.--(BUSINESS WIRE)--City of Hope announced today that it will present data on new findings on bone marrow transplants, immunotherapies and other blood cancer treatments at ASH 62^nd Annual Meeting and Exposition on Dec. 5 to 8, a virtual event.

City of Hope is addressing some of the hardest-to-treat cancers by accelerating innovative clinical research approaches. The comprehensive cancer center was a pioneer in bone marrow and stem cell transplants — and the transplantation program is now one of the largest and most successful programs of its kind in the U.S. For the 15^th year in a row, the Center for International Blood & Marrow Transplant Research has ranked City of Hope as providing exceptional care and strong clinical outcomes for patients who received bone or stem cell transplants; it is the only cancer center to hold this distinction.

During the ASH virtual conference, City of Hope researchers will make presentations on the following and other data:

Title: Efficacy of Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis After Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial

Publication Number: 298

Type: Oral

Session Name: 732. Clinical Allogeneic Transplantation Results III

Session Date and Time: Saturday, Dec. 5, 2020, 2 to 3:30 p.m. ET

Presentation Time: 2:30 p.m.

Presenter: Monzr M. Al Malki, M.D., City of Hope Director of Unrelated Donor BMT Program and Haploidentical Transplant Program, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation

Title: Consolidation With Nivolumab and Brentuximab Vedotin After Autologous Hematopoietic Cell Transplantation in Patients With High-Risk Hodgkin Lymphoma

Publication Number: 472

Type: Oral

Session Name: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Clinical Studies in Hodgkin Lymphoma Session Date and Time: Sunday, Dec. 6, 2020, 2 to 3:30 p.m. ET

Presentation Time: 2:30 p.m.

Presenter: Alex Herrera, M.D., City of Hope Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation

Title: Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination With Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated With Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients With Acute Myeloid Leukemia (AML)

Publication Number: 192

Type: Oral

Session Name: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities

Session Date and Time: Saturday, Dec. 5, 2020, Noon to 1:30 p.m. ET

Presentation Time: 12:45 p.m.

Presenter: Anthony S. Stein, M.D., City of Hope Associate Director, Gehr Family Center for Leukemia Research; Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation

Title: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

Publication Number: 75

Type: Oral

Session Name: 732. Clinical Allogeneic Transplantation: Results I

Session Date and Time: Saturday, Dec. 5, 2020, 7:30 to 9 a.m. ET

Presentation Time: 7:30 a.m.

Study Co-chair: Ryotaro Nakamura, M.D., City of Hope Director, Center for Stem Cell Transplantation; Professor, Department of Hematology & Hematopoietic Cell Transplantation

About City of Hope

City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hope’s translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin and numerous breakthrough cancer drugs are based on technology developed at the institution. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope has been ranked among the nation’s “Best Hospitals” in cancer by U.S. News & World Report for 14 consecutive years. Its main campus is located near Los Angeles, with additional locations throughout Southern California. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.